The BESCT Lung Cancer Program (Biology, Education, Screening, Chemoprevention and Treatment)
Abstract
Our long-term objectives are to define the molecular processes contributing to lung cancer development and progression in order to recognize genetic and phenotypic changes early enough to be reversed with molecularly-targeted therapy and to develop innovative therapeutic approaches to lung cancer. Therefore, the specific goals of this program are to understand molecular alterations in lung cancer, develop lung cancer prevention strategies, and implement experimental molecular approaches to lung cancer. We report herein that aberrant splicing of DNMT3B6 may be involved in tumorigenesis and epigenetic alteration events; anti- tumor effects of COX-2 inhibitors are not dependent on COX-2 expression and are significantly enhanced by retinoic acid; genetic inhibition of the intracellular signaling molecule phosphatidyl inositol 3'-kinase results in induction of apoptosis in lung cancer cell lines; the newly-identified FUS1 gene acts as a potent tumor suppressor in animal models without cytotoxic effects; intravenous injection of the GFE1 peptide results in distribution to pulmonary arteries, veins, bronchial arteries and alveolar capillaries, and reduces the number and size of pulmonary metastases in an animal model of metastatic lung cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2002
- Accession Number
- ADA405338
Entities
People
- Waunki Hong
Organizations
- The University of Texas MD Anderson Cancer Center